Ontology highlight
ABSTRACT: Background
Hodgkin's lymphoma (HL) constitutes 10%-20% of all malignant lymphomas and has a high cure rate (5-year survival, around 90%). Recently, interest has increased concerning preventing secondary complications (secondary cancer, endocrine disorders) in long-term survivors. We aimed to study the epidemiologic features and therapeutic outcomes of HL in children, adolescents, and young adults in Korea.Methods
We performed a multicenter, retrospective study of 224 patients aged < 25 years diagnosed with HL at 22 participating institutes in Korea from January 2007 to August 2016.Results
A higher percentage of males was diagnosed at a younger age. Nodular sclerosis histopathological HL subtype was most common, followed by mixed cellularity subtype. Eighty-one (36.2%), 101 (45.1%), and 42 (18.8%) patients were classified into low, intermediate, and high-risk groups, respectively. Doxorubicin, bleomycin, vinblastine, dacarbazine was the most common protocol (n = 102, 45.5%). Event-free survival rate was 86.0% ± 2.4%, while five-year overall survival (OS) rate was 96.1% ± 1.4%: 98.7% ± 1.3%, 97.7% ± 1.6%, and 86.5% ± 5.6% in the low, intermediate, and high-risk groups, respectively (P = 0.021). Five-year OS was worse in patients with B-symptoms, stage IV disease, high-risk, splenic involvement, extra-nodal lymphoma, and elevated lactate dehydrogenase level. In multivariate analysis, B-symptoms and extra-nodal involvement were prognostic factors for poor OS. Late complications of endocrine disorders and secondary malignancy were observed in 17 and 6 patients, respectively.Conclusion
This is the first study on the epidemiology and treatment outcomes of HL in children, adolescents, and young adults in Korea. Future prospective studies are indicated to develop therapies that minimize treatment toxicity while maximizing cure rates in children, adolescents, and young adults with HL.
SUBMITTER: Lee JM
PROVIDER: S-EPMC7707923 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
Lee Jae Min JM Choi Jung Yoon JY Hong Kyung Taek KT Kang Hyoung Jin HJ Shin Hee Young HY Baek Hee Jo HJ Kook Hoon H Kim Seongkoo S Lee Jae Wook JW Chung Nack Gyun NG Cho Bin B Cho Seok Goo SG Park Kyung Mi KM Yang Eu Jeen EJ Lim Young Tak YT Suh Jin Kyung JK Kang Sung Han SH Kim Hyery H Koh Kyung Nam KN Im Ho Joon HJ Seo Jong Jin JJ Cho Hee Won HW Ju Hee Young HY Lee Ji Won JW Yoo Keon Hee KH Sung Ki Woong KW Koo Hong Hoe HH Park Kyung Duk KD Hah Jeong Ok JO Kim Min Kyoung MK Han Jung Woo JW Hahn Seung Min SM Lyu Chuhl Joo CJ Shim Ye Jee YJ Kim Heung Sik HS Do Young Rok YR Yoo Jae Won JW Lim Yeon Jung YJ Jeon In Sang IS Chueh Hee Won HW Oh Sung Yong SY Choi Hyoung Soo HS Park Jun Eun JE Lee Jun Ah JA Park Hyeon Jin HJ Park Byung Kiu BK Kim Soon Ki SK Lim Jae Young JY Park Eun Sil ES Park Sang Kyu SK Choi Eun Jin EJ Choi Young Bae YB Yoon Jong Hyung JH
Journal of Korean medical science 20201130 46
<h4>Background</h4>Hodgkin's lymphoma (HL) constitutes 10%-20% of all malignant lymphomas and has a high cure rate (5-year survival, around 90%). Recently, interest has increased concerning preventing secondary complications (secondary cancer, endocrine disorders) in long-term survivors. We aimed to study the epidemiologic features and therapeutic outcomes of HL in children, adolescents, and young adults in Korea.<h4>Methods</h4>We performed a multicenter, retrospective study of 224 patients age ...[more]